Group items tagged

The German chronic heart failure (CHF) therapeutics market was worth approximately USD 484.7 million in 2012, with a projected compound annual growth rate (CAGR) of 2.4%, to reach a total of USD 614.8 million in 2022. The launch of Novartis' novel combination drug, LCZ-696 in 2015 will mark the first entrance of a novel branded CHF drug in the past five years, boosting the overall market size considerably till 2022.

2015 Global Retinoblastoma Drugs Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Retinoblastoma Drugs industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

The market increased with an average annual growth of 5.1% between 2007 and 2013. Currently, fresh cheese accounts for 19.3% of the global demand while the remaining market share is divided between the processed cheese (8.2%), powdered and grated cheese (6.5%), blue-veined cheese (2.1%) and other cheese (63.9%). Germany, Italy, Japan, Russia and the United States represent the largest cheese markets. But the strongest annual growth is forecast to occur in Albania (15.4%), Sri Lanka (14.6%), Macedonia (13.9%), Egypt (13.2%) and Ghana (13%).

According to market forecasts, the global renal denervation market will witness significant growth over the next six years, jumping from USD 15.5 million in 2012 to USD 171.7 million by 2019, at a CAGR of 41%. This will mainly be attributable to the intervention's expected approval in major countries. It is stated that across 10 major markets in the major global economies (the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India), only the European Union has approved the use of renal denervation.